Biocon Share Price Prediction for Monday 8 June 2026: F&O Levels and Technical Outlook

June 5, 2026
Posted by: Ankit Jaiswal
Category: News

Biocon Rs 412.30 (-0.90%) on 5 Jun. High Rs 425.00, low Rs 411.50. Support Rs 408, resistance Rs 422. Cautiously Bearish. Monday 8 Jun.

The Biocon prediction for Monday 8 June 2026 is Cautiously Bearish as the stock closed at Rs 412.30 (-0.90%) on Friday 5 June 2026, declining from Rs 416.05. Biocon fell -0.90% to Rs 412.30 on Friday as the pharma/biotech sector saw mild profit-booking; Biocon Biologics US biosimilar pipeline remains the key fundamental driver. The broader Nifty 50 direction on Monday, shaped by the US NFP overnight reaction and RBI post-policy sentiment, will influence this stock. The Biocon prediction for Monday is also shaped by the US Non-Farm Payrolls data released on Friday evening, which will determine Monday’s opening gap direction.

Ankit Jaiswal, Senior Research Analyst at Univest, and Kunal Singla, Associate Director at Univest, provide the F&O levels and technical outlook for the Biocon prediction for Monday 8 June 2026.

Click Here – Get Free Investment Predictions

Table of Contents

Biocon Share Price Data for Monday 8 June 2026

Parameter	Value
CMP (5 June Close)	Rs 412.30
Previous Close	Rs 416.05
Change	-0.90%
Friday High	Rs 425.00
Friday Low	Rs 411.50
Volume	24.79 L
Sector	Pharma/Biotech
Support 1	Rs 408
Support 2	Rs 400
Resistance 1	Rs 422
Resistance 2	Rs 430
Trend	Cautiously Bearish

3 Stocks Building Serious Momentum Right Now

When Univest analysts identify high-conviction opportunities, investors pay attention.

Discover stocks investors are actively accumulating
High-conviction opportunities backed by research
Designed for the next phase of market growth

Unlock the latest Top Stock Picks on Univest

See the Stocks →

Biocon Prediction for Monday: Technical Analysis

Ankit Jaiswal observes that the Biocon prediction for Monday is anchored at Rs 408 support. Biocon fell -0.90% to Rs 412.30 on Friday as the pharma/biotech sector saw mild profit-booking; Biocon Biologics US biosimilar pipeline remains the key fundamental driver. A sustained hold above Rs 408 and a break above Rs 422 would confirm the Cautiously Bearish thesis for the Biocon prediction for Monday 8 June 2026.

Kunal Singla notes that the Biocon prediction for Monday is influenced by the VIX at 15.79 (intraday low 13.46 on Friday) — a constructive signal for controlled directional moves on Monday. Biocon F&O shows OI near Rs 408-410 Put and Rs 422-425 Call for Monday prediction. Pharma sector’s defensive nature provides a partial buffer.

Biocon F&O Analysis for Monday 8 June 2026

Biocon F&O shows OI near Rs 408-410 Put and Rs 422-425 Call for Monday prediction. Pharma sector’s defensive nature provides a partial buffer. The F&O range for Biocon on Monday is between Rs 408 (Put OI support) and Rs 422 (Call OI resistance).

Check the Univest Screener for live NSE/BSE data

Risks for Biocon Prediction for Monday

Biocon Biologics US approval execution risk and regulatory hurdles is the primary risk for the Biocon prediction for Monday.
US NFP reaction on Monday open could create a gap that invalidates the entry zone.
FII selling (net Rs -4,475.76 Cr on 4 June) remains a headwind for all index stocks.
A Nifty 50 breakdown below 23,200 would drag most index stocks lower on Monday.

Conclusion

The Biocon prediction for Monday 8 June 2026 is Cautiously Bearish with Rs 408 as key support and Rs 422 as the critical resistance. Biocon fell -0.90% to Rs 412.30 on Friday as the pharma/biotech sector saw mild profit-booking; Biocon Biologics US biosimilar pipeline remains the key fundamental driver. Ankit Jaiswal and Kunal Singla recommend waiting for the first 15-minute candle on Monday before taking directional positions in Biocon. Data is sourced from open public platforms including NSE and BSE — verify from official exchange sources before any investment decision.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Disclaimer: The securities quoted, if any, are for illustration purposes only and are not recommendatory. This article is for educational purposes only and shall not be considered as investment advice or a recommendation by Univest (Uniresearch Global Pvt Ltd, SEBI Registered Research Analyst INH000013776). Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Data is sourced from open public platforms including NSE and BSE and may be subject to revision. Verify data from official NSE/BSE sources before making any investment decision. Registration granted by SEBI in no way guarantees the performance of the intermediary or provides any assurance of returns to investors. Past performance is not indicative of future results.

Frequently Asked Questions

What is the Biocon prediction for Monday 8 June 2026?

Ans. The Biocon prediction for Monday is Cautiously Bearish. CMP Rs 412.30 (-0.90%) on 5 June. Support Rs 408, resistance Rs 422. Biocon fell -0.90% to Rs 412.30 on Friday as the pharma/biotech sector saw mild profit-booking; Biocon Biologics US biosimilar pipeline remains the key fundamental driver.

What are Biocon support and resistance levels for Monday?

Ans. Support 1: Rs 408. Support 2: Rs 400. Resistance 1: Rs 422. Resistance 2: Rs 430. A close above Rs 422 confirms bullish trend for Biocon on Monday.

What is the Biocon F&O outlook for Monday 8 June 2026?

Ans. Biocon F&O shows OI near Rs 408-410 Put and Rs 422-425 Call for Monday prediction. Pharma sector’s defensive nature provides a partial buffer. The Biocon F&O range for Monday is Rs 408 to Rs 422.

What drives the Biocon prediction for Monday?

Ans. Biocon fell -0.90% to Rs 412.30 on Friday as the pharma/biotech sector saw mild profit-booking; Biocon Biologics US biosimilar pipeline remains the key fundamental driver. The broader Nifty 50 direction on Monday, shaped by the US NFP overnight reaction and RBI post-policy sentiment, will influence this stock. Monday open will reflect the US NFP reaction overnight.

Is Biocon bullish or bearish for Monday 8 June 2026?

Ans. The Biocon prediction for Monday is Cautiously Bearish. Closed Rs 412.30 on Friday declining from Rs 416.05. Biocon Biologics US approval execution risk and regulatory hurdles is the primary risk.

How does India VIX affect Biocon prediction for Monday?

Ans. India VIX closed at 15.79 on Friday, touching an intraday low of 13.46. A VIX below 16 supports cleaner directional moves and reduces whipsaw risk for the Biocon prediction for Monday 8 June.

Should traders go long or short on Biocon Monday?

Ans. For educational reference only: confirm above Rs 422 before longs; use Rs 408 as stop reference. This is not investment advice. Consult a SEBI-registered advisor.

What is the key risk for Biocon on Monday 8 June 2026?

Ans. Primary risk: Biocon Biologics US approval execution risk and regulatory hurdles. Additional risks: US NFP reaction, FII selling pressure, and broader Nifty direction. Use strict stop-losses.

Download the Univest iOS App or Univest Android App to track Biocon live price and get daily F&O predictions.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.